Invalid object name 'Active'.Invalid object name 'Active'. Press Release
rss feed Change Size
Italian Spanish French

Media & Events

Our participation in various global symposiums and events, gives us an opportunity to showcase to the world the entire gammut of products we offer. At ERBA Diagnostics, we encourage regular interactions with our business associates and partners, through seminars and conferences.
Press Release
22 MAY 2013 ERBA Diagnostics, Inc. Announces Notice of Noncompliance with NYSE MKT Continued Listing Standards
Publication : MIAMI--(BUSINESS WIRE)
 ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the “Company”), a fully integrated in vitro diagnostics company, announced today that, on May 17, 2013, the Company received a letter from NYSE MKT LLC (the “Exchange”) stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange’s Company Guide (the “Company Guide”) due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 with the Securities and Exchange Commission (the “SEC”). The letter also states that the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company’s securities from the Exchange.

The Exchange has informed the Company that, in order to maintain its listing on the Exchange, the Company must, by May 31, 2013, submit a plan of compliance (the “10-Q Plan”) addressing how it intends to regain compliance with Sections 134 and 1101 of the Company Guide by August 15, 2013 (the “10-Q Plan Period”). If the Company’s 10-Q Plan is accepted by the Exchange, then the Company may be able to continue its listing during the 10-Q Plan Period, during which time it will be subject to periodic review to determine whether it is making progress consistent with the 10-Q Plan. If the Company’s 10-Q Plan is not accepted by the Exchange, then the Company will be subject to delisting proceedings. Furthermore, if the 10-Q Plan is accepted by the Exchange, but the Company is not in compliance with the continued listing standards of the Company Guide by August 15, 2013, or if the Company does not make progress consistent with the 10-Q Plan during the 10-Q Plan Period, then the Exchange staff will initiate delisting proceedings as appropriate. The Company is working diligently to submit the 10-Q Plan by May 31, 2013 and to regain compliance with the Company Guide by August 15, 2013.

As previously disclosed in its Notification of Late Filing on Form 12b-25 filed with the SEC on May 16, 2013, and in its press release furnished with its Current Report on Form 8-K filed with the SEC on May 15, 2013, the Company has delayed filing its Quarterly Report on Form 10-Q because of delays in filing its Annual Report on Form 10-K for the year ended December 31, 2012, which resulted from unforeseen delays in connection with completing and filing the Company’s consolidated financial statements and the accompanying footnotes, which include the Company’s recently acquired subsidiaries – Drew Scientific, Inc., JAS Diagnostics, Inc. and Drew Scientific Limited Co. Until these matters can be resolved, the Company will not be in a position to file its Quarterly Report on Form 10-Q with the SEC. The Company is working diligently to complete and file its Quarterly Report on Form 10-Q with the SEC, which, as previously disclosed, the Company expects to do on or prior to August 15, 2013.